Kymera Stock 130%: $135 Million Buy Boosts Immunology Bet
A major stake in Kymera Therapeutics highlights growing investor optimism in targeted protein degradation. This artic...
Unsure which cash back card is right for you? Explore different options based on your spending habits and find your ideal match.
25,821 articlesA major stake in Kymera Therapeutics highlights growing investor optimism in targeted protein degradation. This artic...
Stocks wobble as a fresh batch of analyst notes lands on top names like Albemarle, American Express and CME Group. He...
NVIDIA will begin counting stock-based compensation in non-GAAP results from Q1 FY2027, a shift that rekindles a long...
NexaTech Holdings, a $40 billion market-cap company, raised its revenue guidance on stronger-than-expected demand, si...
A single Tuesday remark from a prominent political figure can ripple through the markets. This article explains what ...
A targeted international dividend fund surged 26% over the past year and yields around 3.1%, while broad overseas exp...
JPMorgan warns that retail investors showing signs of fatigue could temper stock demand as Iran-related tensions inte...
When AI dominates headlines, investors often fear every software stock will crumble. This piece digs into whether fig...
If you’ve got $5,000 to invest, these three AI-driven stock picks offer a balanced blend of growth potential and prac...
A fast acquittal may clear charges, but the financial fallout can linger for years. This guide explains how the phras...
A renewable-powered data-center company, Iren, surged after unveiling a multi-year Nvidia partnership and ambitious A...
SpaceX IPO plans could redefine the space economy, but Blue Origin is positioned to challenge. Learn how to evaluate ...